Introduction
We began a study of penicillamine therapy in rheumatoid disease in 1967, encouraged by reports from the U.S.A. (Jaffe, 1963) . When we found that our preliminary results were in general agreement with those of Jaffe (Golding et al., 1968;  1970) a multicentre controlled trial was conducted (Multicentre Trial Group, 1973) . We here report on the further progress of the original group of patients, some of whom have now completed five years of treatment. This is the largest recorded series of patients with the longest period of follow-up, and from it we have concluded that smaller doses of penicillamine than are usually advocated are often effective and cause fewer adverse reactions-a matter of some consequence now that the drug is being more widely prescribed.
"classical" rheumatoid arthritis according to American Rheumatism Association criteria and had had laboratory and clinical evidence of active disease for at least a year. All were attending the Royal Bath Hospital, Harrogate. Their progress was assessed monthly by the following indices: (1) erythrocyte sedimentation rate (Westergren); (2) haemoglobin; (3) sheep cell agglutination test; (4) latex fixation test; (5) duration of morning stiffness (hours); (6) weight; and (7) an observer assessment of the patient's improvement during the previous year, expressed as an integer in a range of -4 to +4 (no change = 0).
Dosage.-Penicillamine was given as 150-mg capsules of penicillamine hydrochloride or as 250-mg tablets of penicillamine base (Distamine). An initial four capsules daily was rapidly increased to 16 (or eight tablets). The incidence of side effects, both major and minor, was such that we later adopted Jaffe's (1968) recommendation of beginning with not more than two capsules and slowly increasing the dose. More recently the starting dose has been 150 mg daily and the maintenance dose has been kept as low as the disease response allowed-often a dose of 300-600 mg is enough. The use of this low-dose regimen has apparently eliminated the serious blood changes seen previously.
Concomitant Therapy.-All of the patients were receiving anti-inflammatory drugs at the beginning of the study and many were on corticosteroid therapy. The latter was slowly withdrawn to conform to a maximum daily dose of 7-5 mg, then further reductions were made as the disease improved. Short courses of prednisolone were given for any acute flare-up. The amount of anti-inflammatory agent given varied, and phenylbutazone was withdrawn because of possible confusion in the interpretation of side effects. Indomethacin, 50-75 mg nightly, was given to overcome morning stiffness but was withdrawn when possible. Intra-articular injections and physiotherapy were prescribed at the clinician's discretion. Copper sulphate solution (0 1%) 5 ml was given daily. Pyridoxine was not given.
Results
Between January 1967 and May 1973 85 patients had been given penicillamine and 69 had taken it for a year or more. The other 16 patients failed to complete one year's treatment for various reasons (table I) . Of the 69 who took the drug for a year or more 24 took it for one full year, 14 for two years, 14 for three years, 14 for four years, and three for five years. Forty-five of the 69 patients are still taking penicillamine; the remaining 24 discontinued it for various reasons (table II). Correlation coefficients were calculated within various dose x initial value subsets of patients to determine whether there was any relation between the changes in index values and the age or experience of a patient. The design of the experiment made more sophisticated tests undesirable. The method was adequate, however, to show that the age or experience of a patient had little or no effect on his or her response to penicillamine. Oneway analyses of variance showed that the different doses were evenly distributed over patients with different initial values of the indices. Thus, though the experiment was unbalanced in design, and the effect of any one explanatory variable could never theoretically be completely divorced from effects of the others, it seemed safe in practice to carry it out.
Preliminary analysis indicated that the initial value of an index had a considerable effect on its change; this was therefore corrected when considering the effect of dose. The correction was performed by subtracting from each change in a given index the average change associated with the initial value of that index in the given year. For each index and each treatment year oneway analyses of variance were carried out to determine whether there was: (a) a significant overall change in the index, (b) a significant difference between the effects of different initial value levels of the index, or (c) a significant difference between the effects of the five different dose levels.
To save space the detailed statistics are not given in the tables of results, except those covering the first full treatment year. Trends appearing in subsequent years are indicated. Detailed statistics will be supplied on request to those interested.
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Haemoglobin.-The figures analysed were the (positive) changes in haemoglobin, and though an increase to a value of 100% or less is considered ain irmlprovement an increase beyond that point is a "deterioration." Similarly, a decrease from a value above 10000' is an "improvement" so long as it does not bring the value below 100%. Patients whose haemoglobin increased from below 100°' to above it and those whose haemoglobin decreased from above 10000 to below it more or less compensated for one another, however, and an analysis based on the change in proximity to the 100% value would probably not have altered the conclusions. In the first year there was a considerable overall improvement, especially among those patients with a very low initial reading. The dose effect was not significant but a higher dose tended to have a slightly better effect (tables III, IV, and V). In the second year more of the patients with low haemoglobin values improved but the overall change was not significant. By the end of the third year all of the patients had a level above 80%.
Erythrocyte Sedimentation Rate.-In the first year there was a pronounced improvement among patients with an initial abnormal E.S.R. Doses of 50-450 mg had a comparatively smaller effect and doses of 600-900 mg a comparatively larger one (tables III, IV, and V). The E.S.R. tended slightly to deteriorate in the second year but not significantly, nor was there any difference between the doses. In subsequent years there was again neither a significant overall change nor a significant difference between doses.
Latex Slide Test.-In the first year there was a considerable overall improvement and though there was no significant differences between doses the 900 mg dose was relatively more efficient than the rest (tables III, IV, and V). In subsequent years there was very little overall change.
Differential Agglutination Test.-In the first year nearly all the patients with abnormal differential agglutination improved significantly. The improvement of abnormal patients continued to a lesser extent during the second year, but little change occurred after that. There was little or no difference between doses in any year (tables III, IV, and V).
Weight.-The overall weight increased significantly during the first year, decreased significantly during the third year, and did not change at other times. The doses did not differ significantly in any year, but the results in the 600-900 mg range were consistently better than average (tables III and VI).
Duration of Morning Stiffness.-In the first year there was a pronounced overall improvement, and the worse the patient the greater the improvement. Doses in the 600-900 mg range were comparatively more effective, and 150-450 mg doses less so (tables III, IV, and V). In subsequent years the improvement continued for those patients with morning stiffness of more than an hour. For all others the overall change was negligible and there was no consistent difference between doses. Morning stiffness (hrs) -1-42 + 0-13
<0-001
Observer assessment 1-39 + 0-13 <0-001
Observer Assessment.-There was a highly significant overall improvement during the first year; this remained significant during the second year and was maintained, though not at a significant level, until the end of the fourth year. Throughout the first four years the 600-900 mg dose was more effective than average (tables III and VII). 1  1  1  1968  16  830  3  3  1  1  2  0  3  1  1969  I 1  945  6  3  3  0  2  1  3  0  1970  I 1  985  4  3  1  1  1  2  3  0  1971  16  546  2  2  0  0  1  1  1  1  1972  6  500  1  0  1  0  0  12  0  0  1973  8  260  0  0  0  0  0  1  0  0   Total .  85   22  15  9  3  16  8  11  3 *Multiple side effects occurred in some patients.
ADVERSE REACTIONS
Withdrawal of the patient from penicillamine treatment because of adverse reactions was necessary in many patients at first when large doses were given. Later, as maintenance doses were progressively reduced, the number of withdrawals because of side effects and the incidence of most adverse reactions fell noticeably (table VIII) . We have seen no cases of agranulocytosis, aplastic anaemia, or severe thrombocytopenia recently despite our increasing use of the drug, though all of these were seen during the first few years, with one death.
Discussion
Undoubtedly pencillamine is an effective antirheumatoid drug, though how it acts is unknown. Nevertheless, rash, loss of taste, nausea, vomiting, and anorexia may all occur, and proteinuria occurs particularly often. Jaffe (1970) regards the effect of penicillamine on the kidney as its greatest drawback. We are less concerned about the renal disorder, which appears to be the result of immune complex nephritis, than about the depression of bone marrow, which is sometimes lethal. Unless proteinuria becomes very heavy (2 g/day) we do not discontinue penicillamine. Platelet counts below 100,000 cm3 we regard as reason for withdrawing penicillamine, and we do not make more than one further attempt to reintroduce the drug after recovery. Our use of lower daily doses of penicillamine than those used in the multicentre trial and elsewhere is the chief reason for making this report, for we believe that the incidence of side effects will be much lower with no loss of therapeutic effect if low maintenance doses are aimed at.
Penicillamine should be started at the lowest convenient dose -one capsule of penicillamine hydrochloride daily. The dose should not be increased until after four weeks, when a further capsule daily may be added. A third capsule may be added after a similar interval. Many patients respond to this dose, but if they do not the dose may be increased at the same rate. Throughout treatment the urine should be tested for proteinuria and platelet and white cell counts made before each change of dose and at least monthly.
A controlled trial of penicillamine in early but active rheumatoid disease is now to be undertaken at several centres to see whether it can prevent deterioration in long-term use.
We All the nine patients presented with classical symptoms and signs of diabetes mellitus, with marked wasting and dehydration associated with polydipsia and polyuria and in some cases with ketosis. They had glycosuria and a raised fasting blood sugar. They all required insulin followed by oral hypoglycaemic therapy for some months. They then clinically remitted. Five of the cases are not reported in detail here because they defaulted from follow-up, presumably because they remained well.
During follow-up the patients tested their urine with Clinitest tablets daily for the first four to eight weeks and thereafter on three days a week. At first no sugar or glucose powder was allowed but otherwise the normal African diet of mostly carbohydrate foods such as cassava, yam, maize, and rice was unrestricted. The reason for not restricting the diet was that all the patients when first seen were wasted from both the acute liver disease, with its associated marked anorexia for protein and fatty foods, and the diabetes. On a free diet and insulin the diabetes was quickly brought under control and, since the need for insulin progressively diminished, there was no need to interfere with the usual diet. After varying periods of follow-up a modified corticosteroid-dlucose tolerance test (Fajans and Conn, 1954) was done, in whici each patient was given a total of 40 mg of prednisolone in four divided doses the day before he reported as an outpatient for a standard glucose-tolerance test. Blood sugars were estimated on capillary blood samples by the method of Folin and Wu.
Case 1
The patient, a 39-year-old printer, was first seen and admitted to hospital in December 1970 with polyuria, polydipsia, and loss of weight over the preceding two weeks. There was no family history of diabetes mellitus. He was taken ill in September 1970 with severe infectious hepatitis. An epidemic of jaundice had been raging in the
